Sideris Pharmaceuticals racks up $32 mln, also could be acquired by Novartis for up to $300 mln
Sideris Pharmaceuticals said Tuesday that it has closed $32 million in Series A financing. MPM Capital led the round with participation from Hatteras Venture Partners and Osage University Partners. In addition to the financing, Sideris has inked an agreement with Novartis Pharmaceuticals that grants Novartis the exclusive right to acquire Sideris in a transaction that could reach up to $300 million. Also, Sideris has named Dr. Ansbert Gadicke and Dr. Kazumi Shiosaki, managing directors of MPM Capital and Dr. Doug Reed, general partner of Hatteras Venture Partners, to the Sideris board of directors. Sideris Pharmaceuticals is a biopharmaceutical company that develops treatments for transfusion-related iron overload.
22 October 2013•4 mins read
